Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Cited In for PubMed (Select 2442609)

1.

Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer.

Davalieva K, Kiprijanovska S, Komina S, Petrusevska G, Zografska NC, Polenakovic M.

Proteome Sci. 2015 Jan 29;13(1):2. doi: 10.1186/s12953-014-0059-9. eCollection 2015.

2.

The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen.

Cho HJ, Shin SC, Cho JM, Kang JY, Yoo TK.

Prostate Int. 2014 Dec;2(4):196-202. doi: 10.12954/PI.14060. Epub 2014 Dec 30.

3.

Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.

Olsen L, Campos B, Winther O, Sgroi DC, Karger BL, Brusic V.

BMC Med Genomics. 2014 Dec 8;7 Suppl 3:S2. doi: 10.1186/1755-8794-7-S3-S2. Epub 2014 Dec 8.

4.

Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.

Neeb A, Hefele S, Bormann S, Parson W, Adams F, Wolf P, Miernik A, Schoenthaler M, Kroenig M, Wilhelm K, Schultze-Seemann W, Nestel S, Schaefer G, Bu H, Klocker H, Nazarenko I, Cato AC.

Oncotarget. 2014 Sep 30;5(18):8681-9.

5.

DNA methylation gene-based models indicating independent poor outcome in prostate cancer.

Vasiljević N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT.

BMC Cancer. 2014 Sep 6;14:655. doi: 10.1186/1471-2407-14-655.

6.

Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G, Lazzeri M.

Korean J Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub 2014 Jul 11.

7.

Allelic variability in PSA & AR genes: a novel biomarker on the horizon for carcinoma prostate.

Dogra PN.

Indian J Med Res. 2014 Mar;139(3):337-8. No abstract available.

8.

Kallikreins as biomarkers for prostate cancer.

Hong SK.

Biomed Res Int. 2014;2014:526341. doi: 10.1155/2014/526341. Epub 2014 Apr 7. Review.

9.

Trial Watch: DNA vaccines for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e28185. Epub 2014 Apr 1. Review.

PMID:
24800178
10.

Emerging PSA-based tests to improve screening.

Bryant RJ, Lilja H.

Urol Clin North Am. 2014 May;41(2):267-76. doi: 10.1016/j.ucl.2014.01.003. Epub 2014 Feb 26. Review.

PMID:
24725489
11.

Cancer diagnostic classifiers based on quantitative DNA methylation.

Lorincz AT.

Expert Rev Mol Diagn. 2014 Apr;14(3):293-305. doi: 10.1586/14737159.2014.897610. Review.

12.
13.

Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.

Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y.

J Cancer. 2014 Jan 29;5(3):182-91. doi: 10.7150/jca.6799. eCollection 2014.

14.

Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.

Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y.

J Cancer. 2014 Jan 5;5(2):103-14. doi: 10.7150/jca.6890. eCollection 2014.

15.

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.

Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U.

Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71. doi: 10.1007/s10555-013-9470-4. Review.

16.

Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.

Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider T, Paša-Tolić L, Jenster G.

PLoS One. 2013 Dec 31;8(12):e82589. doi: 10.1371/journal.pone.0082589. eCollection 2013.

17.

Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population.

Rajaei M, Momeni A, Kheiri S, Ghaheri H.

J Res Med Sci. 2013 May;18(5):387-90.

18.

Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.

Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA, Mukhtar H.

Carcinogenesis. 2014 Feb;35(2):415-23. doi: 10.1093/carcin/bgt321. Epub 2013 Sep 26.

19.

Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.

Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus K, Seifert HH, Strebel RT, Knuth A, Samaras P, Müntener M.

J Cancer. 2013 Aug 29;4(7):597-605. doi: 10.7150/jca.7123. eCollection 2013.

20.

Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases.

Yoon IS, Shin TY, Kim SI, Park SK, Jang HI, Choi JB, Ahn HS, Kim YS, Kim SJ.

Korean J Urol. 2013 Sep;54(9):593-7. doi: 10.4111/kju.2013.54.9.593. Epub 2013 Sep 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk